TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34167284
Drug: Conventional dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressing (CD) group - normal temperature boric acid solution wet dressing, 3 times a day
Study: 33028661
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment of COVID-19 (specific details not provided)
Study: 36376399
Drug: Ag NPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag NPs at 50 µg/mL
Study: 36376399
Drug: Ag NPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag NPs at 250 µg/mL
Study: 35470199
Drug: Open dialogue
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open dialogue about complementary and alternative medicine (OD‐CAM)
Study: 35907370
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (40 ml)
Study: 35907370
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%, 40 ml)
Study: 36128889
Drug: B-vitamin intervention
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin intervention (combined folic acid 200 μg, vitamin B12 10 μg, vitamin B6 10 mg, riboflavin 5 mg)
Study: 33266022
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (200,000 IU bolus at week 0 followed by 20,000 IU/day for 7 weeks)
Study: 33266022
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D combined with infliximab (5 mg/kg at weeks 0, 2, and 6)
Study: 32163420
Drug: Intravenous rehydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rehydration
Study: 36419043
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Low-dose CT scans and 3D models printed before inexperienced surgeons performed surgeries
Study: 36419043
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Standard-dose CT scans and 3D models printed before experienced surgeons performed surgeries
Study: 36419043
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Standard-dose CT scans, operations performed by inexperienced surgeons
Study: 36419043
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: Standard-dose CT scans, operations performed by experienced surgeons
Study: 32012257
Drug: Family-Focused Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Focused Treatment for Adolescents (FFT-A)
Study: 35749864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily activities)
Study: 34015241
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg three times per week
Study: 36002117
Drug: 5,000 mg
Normalized name: garlic 5,000 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 mg ASA orally once daily from D 120 until parturition (group ASA1)
Study: 37031887
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg twice daily)
Study: 35932798
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in treatment plans after pneumonia
Study: 34126053
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of RAS inhibition
Study: 39265173
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg)
Study: 34810364
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement at 8 weeks with A-PRF
Study: 34810364
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement at 6 weeks with A-PRF
Study: 35304019
Drug: Ginger capsules
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger capsules (250 mg, four capsules)
Study: 35304019
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (four capsules)
Study: 32236602
Drug: Glutathione (ROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (ROS inhibitor)
Study: 34127107
Drug: Lurasidone (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20-80 mg/d)
Study: 32334460
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisolone (5 mg daily for two months)
Study: 33512942
Drug: Protocol-guided strategy
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-guided strategy utilizing stroke volume variation to guide administration of bolus fluid
Study: 33160266
Drug: Single-facet G-coefficients
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-facet G-coefficients averaged across laboratories.
Study: 33517741
Drug: Blind injection
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injection
Study: 35460158
Drug: Intralesional tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional tranexamic acid (TXA) 4 mg/ml
Study: 33028796
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no surface treatment)
Study: 32927075
Drug: High-dose digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose digestive enzyme treatment (Excelase: 3.0 g/day; Pancreatin: 3.0 g/day; Berizym: 3.0 g/day; Toughmac-E: 3.0 g/day)
Study: 32927075
Drug: Normal-dose digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose digestive enzyme treatment (Excelase: 3.0 g/day)
Study: 38844941
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg or 10 mg)
Study: 38844941
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg)
Study: 35101183
Drug: FeNO plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeNO plus symptom-guided treatment
Study: 35101183
Drug: Symptom-guided treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-guided treatment alone (standard care)
Study: 34562328
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol with ascorbic acid (PEG-Asc)
Study: 36220337
Drug: Intensive systolic
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systolic blood pressure (SBP) treatment
Study: 32668428
Drug: Intravenous MEPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MEPD injection
Study: 32668428
Drug: Intratympanic MEPD
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic MEPD injection
Study: 36469914
Drug: Dapagliflozin, 10
Normalized name: Dapagliflozin, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin, 10 mg once daily
Study: 33174126
Drug: Antibiotic time-out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic time-out protocol
Study: 33622590
Drug: Multivalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivalent vaccine containing nine serogroups (A, B, C, D, E, F, G, H, I)
Study: 33622590
Drug: Sequential bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bivalent vaccines
Study: 33622590
Drug: Monthly foot-bathing
Normalized name: Fungi-Nail Toe and Foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly foot-bathing
Study: 32279529
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (Olmesartan), duration 1 year
Study: 32769524
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (10%) with microneedling
Study: 32531798
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg every 2 weeks (Q2W)
Study: 33953123
Drug: Methadone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone + disulfiram (250 mg/day)
Study: 33039992
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (meprednisone or prednisone for 6 months)
Study: 35659776
Drug: Sleep-Extend intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep-Extend intervention (6 weeks of using a Fitbit, weekly digital content, and weekly coaching)
Study: 35037278
Drug: High-dose topiramate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose topiramate (up to 250 mg/day)
Study: 35037278
Drug: Low-dose topiramate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose topiramate (up to 125 mg/day)
Study: 34852779
Drug: Needle-free system
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free system (Comfort-In™) with 0.3 mL anesthesia (2% lidocaine and 1/80000 epinephrine)
Study: 39013870
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks)
Study: 34584971
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L PEG+Asc
Study: 32962934
Drug: Continuous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous remifentanil infusion (R)
Study: 33337491
Drug: Vida Sana
Normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vida Sana intervention (culturally adapted lifestyle intervention with family-based orientation and 22 group sessions over 12 months, plus monthly emails for an additional 12 months)
Study: 35344089
Drug: Standard position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard position (300 µm pre- and post-anterior capsule)
Study: 32907904
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg elobixibat (EXB) monotherapy
Study: 33739852
Drug: Low-risk patients
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk patients compared to standard-risk patients with identical therapy
Study: 32921069
Drug: Aggressive metastasis-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive metastasis-directed therapy (MDT) with surgery and/or hypofractionated image-guided radiation therapy (HIGRT)
Study: 32921069
Drug: Improved systemic
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved systemic therapies (targeted agents and immunotherapy)
Study: 35296289
Drug: Information related
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information related to AstraZeneca's vaccine safety
Study: 35234092
Drug: 2DR (bDRV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2DR (bDRV 800 mg + dolutegravir 50 mg)
Study: 32299093
Drug: MDS‐associated mutations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDS‐associated mutations after high-dose therapy
Study: 32801257
Drug: Split-dose (SPD)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose (SPD) 2 L polyethylene glycol electrolyte solution, 1 L PEG between 8-9 pm the day before and 1 L PEG between 5-6 am on the day of colonoscopy.
Study: 32801257
Drug: Split-dose (SPD)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose (SPD) group
Study: 32801257
Drug: Single-dose (SID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SID) group
Study: 34481095
Drug: 6-Hz tACS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-Hz tACS for 26.67 min daily for three days (Long Exposure Theta group)
Study: 34481095
Drug: 6-Hz tACS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-Hz tACS for 5.33 min daily (Short Exposure Theta group)
Study: 39697620
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus endocrine therapy (ET)
Study: 39463748
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET) alone
Study: 34398667
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg base/kg of body weight) plus primaquine (0.5 mg base/kg/day for 14 days)
Study: 34398667
Drug: Dihydroartemisinin-piperaquine (dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine (0.5 mg base/kg/day for 14 days)
Study: 34398667
Drug: Dihydroartemisinin-piperaquine (dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine (1 mg/kg/day for 7 days)
Study: 34398667
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg base/kg of body weight) plus primaquine (1 mg/kg/day for 7 days)
Study: 32166899
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day Linagliptin
Study: 32711565
Drug: Pidotimod (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (2 vials of 400 mg daily) with betamethasone 0.5-1 mg on need
Study: 32711565
Drug: Betamethasone 0.5-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.5-1 mg on need
Study: 35340120
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) 325 mg every 12 hours plus f‐TCC (fluocinolone‐based triple combination cream) every 24 hours
Study: 35340120
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) 325 mg every 12 hours
Study: 32243384
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with conventional drug treatment
Study: 34353696
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IL-6 elevation and high serum glucose levels
Study: 35794044
Drug: Late oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late oral feeding
Study: 34583100
Drug: Cognitive‐Behavioral Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Therapy for Seasonal Affective Disorder (CBT‐SAD)
Study: 34015829
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (Group 2)
Study: 34015829
Drug: Guideline-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed therapy (Group 1)
Study: 35361630
Drug: Nintedanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib plus chemotherapy
Study: 32857933
Drug: Escitalopram (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (15 mg/d forced titration to 20 mg/d)
Study: 32943094
Drug: Monitoring adherence
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring adherence and inhalation technique without feedback
Study: 33084254
Drug: Mirtazapine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (titrated up to 45 mg/d for 8 weeks)
Study: 35620951
Drug: Compound lidocaine
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound lidocaine cream with roller microneedles for 10 min, followed by rolling for 20 min (30 min test side)
Study: 34424217
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea mouthwash (13% infusion prepared with 13 g of green tea in 100 mL saline solution)
Study: 35531572
Drug: Whitegold Office
Normalized name: Office First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitegold Office 35% (WGO) bleaching agent
Study: 35531572
Drug: Whiteness HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whiteness HP Auto Mixx 35% (WHP) bleaching agent
Study: 35531572
Drug: Combined bleaching
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bleaching agents (WGO and WHP)
Study: 35727580
Drug: Varenicline, 1
Normalized name: Varenicline, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline, 1 mg, twice daily for 12 weeks
Study: 32539908
Drug: DBV712 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBV712 250 µg epicutaneous patch
Study: 37345996
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention
Study: 33288333
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy rehabilitation program combined with music therapy
Study: 33288333
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy rehabilitation program without music therapy
Study: 35792365
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg
Study: 35344737
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.9 g docosahexaenoic acid and 0.22 g eicosapentaenoic acid)
Study: 32544011
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg CoQ10 capsules per day
Study: 32955672
Drug: Standard LRYGB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard LRYGB (S‐LRYGB) (RL 150 cm, BPL 60 cm, and variable CC length)
Study: 36184601
Drug: L-BAIBA 1500
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BAIBA 1500 mg (B1500)
Study: 36184601
Drug: L-BAIBA 500
Normalized name: arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-BAIBA 500 mg (B500)
Study: 36184601
Drug: L-BAIBA 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BAIBA 250 mg (B250)
Study: 36184601
Drug: Valine 1500
Normalized name: Valine
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valine 1500 mg (V1500)
Study: 33455201
Drug: Non-fluorescent ELP
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fluorescent ELP fusion proteins co-transfected with a fluorescent ELP marker; specific dosage and duration not mentioned.
Study: 33455201
Drug: Single transfected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single transfected treatments of ELP fusions; specific dosage and duration not mentioned.
Study: 33196146
Drug: 4.0-mm annular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0-mm annular treatment zone
Study: 32100502
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding therapy combined with rehabilitation training
Study: 34921121
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm (specific treatment not detailed)
Study: 39264623
Drug: Alteplase (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (0.9 mg/kg)
Study: 35525250
Drug: Tenecteplase (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.4 mg/kg)
Study: 33223426
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg GSK958108
Study: 34048940
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day
Study: 33865691
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual arm, n = 335
Study: 32877576
Drug: rSARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rSARS-CoV-2 vaccine with Matrix-M1 adjuvant
Study: 32877576
Drug: rSARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rSARS-CoV-2 vaccine without Matrix-M1 adjuvant
Study: 34936382
Drug: Doxycycline 20
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 20 mg
Study: 35403213
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of fresh cow's milk (ED05)
Study: 32110882
Drug: Ketamine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.15 mg/kg (LBM))
Study: 32471492
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Patient Health Questionnaire (PHQ‐9) as a PROM within 2 weeks of diagnosis and at follow‐up 4 weeks later. General practitioners trained in interpreting scores and providing feedback.
Study: 35909461
Drug: Trusopt® eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trusopt® eye drops solution
Study: 39591972
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs)
Study: 33387930
Drug: EMS treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMS treatments
Study: 33387930
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with published treatment time data from other EMS systems
Study: 33245708
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music once a day)
Study: 35469036
Drug: LIFT +
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIFT + BM-MNC injection
Study: 32251757
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation therapy
Study: 36123681
Drug: Complete vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete vaccination with Gam-COVID-Vac (14 days or more after the second dose)
Study: 38647051
Drug: Investigator-assigned therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir)